已保存。查看收藏列表。 周五,RBC Capital Markets将Celestica(纽约证券交易所代码:CLS)的目标股价从115.00美元上调至140.00美元,同时维持"优于大市"评级。目前,该股交易价格为131.66美元,接近52周高点。InvestingPro分析显示,该股的交易价格高于其公允价值。此次调整是在公司报告强劲财务业绩并提供乐观预期后做出的,该股在过去一年中取得了令人印象 ...
The Swan is supposed to be fairytale makeover television, but when the cast discover they're really contestants in a plastic surgery face-off, it becomes a grueling nightmare.